Press release Archives - Artios Pharma

IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer

13 April 2023 | Press release

Capture

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

9 February 2023 | Press release

Article-1-1-400×400

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

10 August 2022 | Press release

Artios Appoints Samantha Truex to Board of Directors

23 June 2022 | Press release

For press release

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

5 April 2022 | Press release

shutterstock_1184899237 4 MB

Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair

16 November 2021 | Press release

nora

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

28 September 2021 | Press release

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

27 July 2021 | Press release

nasdaq-2-400×400

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

17 June 2021 | Press release

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

7 April 2021 | Press release

1 2 3 Next »

© Artios Pharma 2023 | Website by Granite 5

Terms & conditions | Privacy policy | Site map